These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 25278002

  • 1. Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.
    Sherid M, Sifuentes H, Sulaiman S, Samo S, Husein H, Tupper R, Thiruvaiyaru D, Spurr C, Sridhar S.
    Digestion; 2014; 90(2):137-46. PubMed ID: 25278002
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P, Duraj I, Szlagowska L, Ciastkowska A, Broncel M.
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [Abstract] [Full Text] [Related]

  • 3. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.
    BMJ; 2015 Apr 24; 350():h1857. PubMed ID: 25910928
    [Abstract] [Full Text] [Related]

  • 4. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
    Chang HY, Zhou M, Tang W, Alexander GC, Singh S.
    BMJ; 2015 Apr 24; 350():h1585. PubMed ID: 25911526
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun 24; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 10. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 24; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 11. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
    Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA, Nedios S, Dinov B, Hindricks G, Richter S, Bollmann A.
    Europace; 2014 Jul 24; 16(7):1028-32. PubMed ID: 24489073
    [Abstract] [Full Text] [Related]

  • 12. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
    Loke YK, Pradhan S, Yeong JK, Kwok CS.
    Br J Clin Pharmacol; 2014 Oct 24; 78(4):707-17. PubMed ID: 24617578
    [Abstract] [Full Text] [Related]

  • 13. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S.
    Europace; 2014 Aug 24; 16(8):1137-44. PubMed ID: 24550347
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
    Fontaine GV, Mathews KD, Woller SC, Stevens SM, Lloyd JF, Evans RS.
    Clin Appl Thromb Hemost; 2014 Oct 24; 20(7):665-72. PubMed ID: 24875781
    [Abstract] [Full Text] [Related]

  • 16. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
    Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY.
    Ann Med; 2014 Dec 24; 46(8):672-8. PubMed ID: 25174259
    [Abstract] [Full Text] [Related]

  • 17. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C.
    Cerebrovasc Dis; 2013 Dec 24; 36(2):115-9. PubMed ID: 24029592
    [Abstract] [Full Text] [Related]

  • 18. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 24; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 19. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.
    Int Angiol; 2014 Aug 24; 33(4):301-8. PubMed ID: 25056161
    [Abstract] [Full Text] [Related]

  • 20. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.
    Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC.
    Gastroenterology; 2015 Sep 24; 149(3):586-95.e3. PubMed ID: 25960019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.